Logo image of NTLX.CA

NEUROTHERA LABS INC (NTLX.CA) Stock Fundamental Analysis

Canada - TSX Venture Exchange - TSX-V:NTLX - CA60700R1073 - Common Stock

0.26 CAD
+0.03 (+10.64%)
Last: 11/25/2025, 7:00:00 PM
Fundamental Rating

2

Overall NTLX gets a fundamental rating of 2 out of 10. We evaluated NTLX against 0 industry peers in the Unkown industry. While NTLX has a great health rating, there are worries on its profitability. NTLX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NTLX has reported negative net income.
NTLX had a negative operating cash flow in the past year.
NTLX.CA Yearly Net Income VS EBIT VS OCF VS FCFNTLX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 -50K -100K -150K -200K -250K

1.2 Ratios

Industry RankSector Rank
ROA -20.29%
ROE -23.84%
ROIC N/A
ROA(3y)-12.81%
ROA(5y)N/A
ROE(3y)-14.26%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NTLX.CA Yearly ROA, ROE, ROICNTLX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 -5 -10 -15 -20 -25

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NTLX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NTLX.CA Yearly Profit, Operating, Gross MarginsNTLX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, NTLX has about the same amount of shares outstanding.
There is no outstanding debt for NTLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NTLX.CA Yearly Shares OutstandingNTLX.CA Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 5M 10M 15M
NTLX.CA Yearly Total Debt VS Total AssetsNTLX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 200K 400K 600K 800K 1M

2.2 Solvency

NTLX has an Altman-Z score of 17.63. This indicates that NTLX is financially healthy and has little risk of bankruptcy at the moment.
NTLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 17.63
ROIC/WACCN/A
WACCN/A
NTLX.CA Yearly LT Debt VS Equity VS FCFNTLX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 500K 1M

2.3 Liquidity

A Current Ratio of 6.71 indicates that NTLX has no problem at all paying its short term obligations.
A Quick Ratio of 6.71 indicates that NTLX has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 6.71
Quick Ratio 6.71
NTLX.CA Yearly Current Assets VS Current LiabilitesNTLX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 200K 400K 600K 800K 1M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for NTLX have decreased strongly by -167.50% in the last year.
EPS 1Y (TTM)-167.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NTLX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTLX.CA Price Earnings VS Forward Price EarningsNTLX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NTLX.CA Per share dataNTLX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.01 0.02 0.03 0.04

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NTLX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROTHERA LABS INC

TSX-V:NTLX (11/25/2025, 7:00:00 PM)

0.26

+0.03 (+10.64%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners16.57%
Ins Owner ChangeN/A
Market Cap4.71M
Revenue(TTM)N/A
Net Income(TTM)-212.60K
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.28
P/tB 5.28
EV/EBITDA N/A
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0
BVpS0.05
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.29%
ROE -23.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-12.81%
ROA(5y)N/A
ROE(3y)-14.26%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.71
Quick Ratio 6.71
Altman-Z 17.63
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-167.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-39.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-99.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-99.72%
OCF growth 3YN/A
OCF growth 5YN/A

NEUROTHERA LABS INC / NTLX.CA FAQ

What is the ChartMill fundamental rating of NEUROTHERA LABS INC (NTLX.CA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NTLX.CA.


What is the valuation status of NEUROTHERA LABS INC (NTLX.CA) stock?

ChartMill assigns a valuation rating of 0 / 10 to NEUROTHERA LABS INC (NTLX.CA). This can be considered as Overvalued.


How profitable is NEUROTHERA LABS INC (NTLX.CA) stock?

NEUROTHERA LABS INC (NTLX.CA) has a profitability rating of 0 / 10.